Glucagon Modulation of Ghrelin Secretion

Charite University, Berlin, Germany38 enrolled

Overview

As a counterregulatory hormone for insulin, glucagon plays a critical role in maintaining glucose homeostasis in vivo. It is well known that intramuscular glucagon administration stimulates growth hormone (GH), adrenocorticotropic hormone (ACTH) and cortisol release in humans. Recently, it has been shown that glucagon induces a remarkable decrease in ghrelin levels. The mechanisms underlying this effect are unclear and the role of changes in glucose, insulin, glucagon-like peptide-1 (GLP-1) and catecholamines are widely discussed. The aim of the present study is to further evaluate the effect of glucagon on ghrelin secretion and the possible role of the above mentioned factors in mediating this effect.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

BASIC_SCIENCE

Masking

TRIPLE

Enrollment

Conditions

Healthy Subjects Obesity Diabetes Mellitus, Type 1

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 60 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects \> 18 and \< 60 years old. * Patients with diabetes type 1 should fulfill the following criteria: * ICT Insulin therapy was necessary within the first 3 months after diagnosis; * HbA1c-Wert \< 7%. Exclusion Criteria: * Diabetes type 1 or 2 (for the healthy group). * Biochemical evidence of impaired hepatic or renal function. * History of cardiovascular disease. * Uncontrolled hypertension. * Current inflammatory, malignant or psychiatric disease. * Pregnancy

Outcomes

Primary Outcomes

Changes in satiety scale, total and acylated ghrelin concentrations.

Time frame: During 240 min after Glucagon/Placebo administration.

Secondary Outcomes

Changes in glucose, insulin and NEFA concentrations.